OCT 30, 2014 06:00 AM PDT
A platform for combining the results of WES and RNA-seq analysis
Presented at the Cancer: Research, Discovery and Therapeutics Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
12 46 1397

Speakers:
  • Director, Clinical Analytics and Workflow Products, CLC Bio, a Qiagen company
    Biography
      Naomi is greatly experienced within the field of bioinformatics from where she has gained a tremendous amount of customer, product, and sequencing experience through the past 15 years. Naomis pre-business experience is loaded with nucleic acids and oncology at Bristol-Myers Squibb and The Wistar Institute, along with an MBA from La Salle University. Naomi has also been working 10 years as a Product Manager and nearly five years as an NGS Key Account Manager before heading the product management of Clinical Analytics and Workflow products at QIAGEN.

    Abstract:
    Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq). Many analyses, such as comparison of tumor and normal cells, include comparison of variant calls. In this webinar, we will illustrate the benefits of leveraging read mappings in the comparison of WES and RNA-seq data using CLC Cancer Research Workbench. The CLC platform provides a number of tools, together building up a workflow, for analyzing WES and RNA-seq reads and for comparing the results. From this webinar you will learn how to analyse and compare variants from two patients using built-in workflows in CLC Cancer Research Workbench; Analysis steps include filtering results for tumor-specific variants, identifying variants from both WES and RNA-seq data, searching RNA-seq read mappings for variants previously called from exome data, and recovering previously detected variants in the WES data directly from the RNA-seq read mappings.

    Show Resources
    Loading Comments...